NCT05431179 - A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma | Biotech Hunter

Timeline

Start Date

March 31, 2023

Primary Completion Date

November 30, 2026

Study Completion Date

December 31, 2026

Conditions

Lymphoma, Mantle-CellLymphomaLymphoproliferative DisordersLymphatic DiseasesImmunoproliferative DisordersImmune System DiseasesLymphoma, Non-HodgkinLymphoma, B-Cell

Interventions

DRUG

Zilovertamab

After 16 weeks in the open-label Ibrutinib phase, participants will receive zilovertamab (600mg) administered by IV every 2 weeks for 3 administrations and then every 4 weeks thereafter.

DRUG

Ibrutinib

All participants will receive oral Ibrutinib (560mg) daily.

DRUG

Placebo

After 16 weeks in the open-label Ibrutinib phase, participants will receive placebo administered by IV every 2 weeks for 3 administrations and then every 4 weeks thereafter.